Genentech’s first implantable drug delivery system shows promising results in phase 2 wet AMD trial

July 10, 2018

Dr. Carl Regillo, a study investigator for Genentech’s first refillable eye implant, discusses the promising results in a phase 2 trial. The Port Delivery System is designed to deliver a new formulation of Lucentis' active ingredient, ranibizumab, continuously to wet age-related macular degeneration patients to avoid monthly eye injections. Read more about the new surgical implant here.


Comments are closed.